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Background. In animal models, polycystic kidneys are susceptible to acute kidney injury (AKI). We examined the occurrence of
AKI in a cohort of autosomal dominant polycystic kidney disease (ADPKD) and non-ADPKD patients with acute pneumonia.
Design. All ADPKD patients admitted to Mayo Clinic Rochester for pneumonia from January 1990 to April 2010 were examined.
Sixty-three patients had lobar inﬁltration and consolidation on chest X-ray. After excluding patients on dialysis, with organ
transplantation, and on chronic immunosuppression, 24 remaining ADPKD patients were enrolled. Twenty-three of the 24
were matched with 92 (1:4 ratio) non-ADPKD pneumonia patients based on their baseline eGFR. AKI was deﬁned as serum
creatinineelevation≥0.3mg/dL.Results.Sixteenofthe23ADPKDpatients(69.6%)and36ofthe92(39.1%)non-ADPKDpatients
developed AKI, P = 0.008. In both groups, those who developed AKI had a lower baseline eGFR (41.1±5.00 versus 58.7±11.8i n
ADPKD and 40.2±3.65 versus 51.8±2.24mL/min/1.73m2 in the non-ADPKD group), more intensive care unit admissions, and
longer hospital stays. AKI was associated with a reduced survival in both groups. Conclusions. Patients with ADPKD admitted for
acute pneumonia had more frequent episodes of AKI than non-ADPKD patients with comparable kidney function.
1.Introduction
Acute kidney injury (AKI) occurs in 7–18% of all hos-
pitalized patients [1] and is an independent predictor of
mortality [2]. Risk factors for the development of AKI
include infection, sepsis, medication toxicity, intravenous
contrast administration, and major surgeries. Patients with
underlying kidney disease are more susceptible to AKI in the
setting of infection [3].
Autosomal dominant polycystic kidney disease
(ADPKD) is a common, inherited disease, characterized by
formation of kidney cysts due to renal tubular dilatation,
leading to cystic kidney enlargement and kidney failure
in more than half of the aﬀected patients by age 50–
70 [4]. Kidney tubules in ADPKD exhibit features of
dediﬀerentiation with elevated rates of proliferation and
apoptosis at baseline [5, 6]. In orthologous polycystic
kidney mouse models, cystic kidneys exhibit an increased
susceptibilitytoAKIinducedbyischemic-reperfusioninjury,
with changes seen as early as 48 hours after the insult [7–9].
Whether humans with ADPKD have the same increased
susceptibility to AKI as the animal models of ADPKD is
unknown.
Acute pneumonia, mild or severe, has been shown to
cause AKI in a fraction of patients, leading to an increased
in-hospital and one-year mortality [10, 11]. In this study, we
examined the incidence, severity, and associated mortality of
AKI in a cohort of patients with and without ADPKD who
were hospitalized for pneumonia.
2.SubjectsandMethods
2.1. Study Protocol and Data Collection. The study was
approved by the Institutional Review Board. A total of
345 patients with ADPKD who were cared for at Mayo
Clinic Rochester for acute pneumonia from January 19902 International Journal of Nephrology
to April 2010 were identiﬁed through the institutional
radiology database. Sixty-three of the 345 patients were
admitted to the hospital for treatment. The 63 patients
were enrolled for analysis. Non-ADPKD patients admitted
for pneumonia with a comparable estimated glomerular
ﬁltration rate (eGFR; within ±10mL/min/1.73m2) during
the same time period were enrolled as the control group. All
patients were treated in the general internal medicine ward
or medical intensive care unit (ICU). Estimated GFR was
determined from serum creatinine concentration using the
4-variable Modiﬁcation of Diet in Renal Disease (MDRD)
Equation [12]. Patients with the following conditions were
excluded: age younger than 18, end-stage kidney failure on
renal replacement therapy, any organ transplantation, on
chronic immunosuppressive therapy, systemic vasculitis, or
incomplete medical information.
Pneumonia was deﬁned as clinical evidence of infection
with an accompanying chest X-ray showing new inﬁltra-
tion and/or consolidative process, not due to atelectasis.
Radiological evidence of pneumonia was reconﬁrmed by a
radiologist (RPH). For patients with several admissions for
pneumonia during the study period, only the most recent
pneumonia episode was studied. The severity of pneumonia
was graded upon admission using a ﬁve-point scoring
system (CURB-65 score) with one point assigned for each
of the following: confusion, urea >7mmol/L, respiratory
rate ≥30/min, low systolic blood pressure (<90mmHg), low
diastolic blood pressure (≤60mmHg), and age ≥65 years.
This scoring system was validated with a higher score being
associated with higher risk of mortality [13].
Baseline serum creatinine (mg/dL) was deﬁned as the
creatinine concentration on admission and was conﬁrmed
by reviewing prior creatinine values within six months of
admission. AKI was considered present if peak serum cre-
atinine concentration during the hospital stay increased by
≥0.3mg/dL over the baseline, with or without oliguria. The
severity of AKI was determined using creatinine deﬁnitions
of the RIFLE criteria [14]. The RIFLE criteria classiﬁes
AKI into the following: stage I (Risk) is deﬁned as serum
creatinine elevation ≥1.5-times the baseline creatinine; stage
II (Injury) ≥2-times the baseline; stage III (Failure) ≥3-
times the baseline or creatinine ≥4.0mg/dL; complete loss of
kidney function requiring renal replacement therapy. Patient
comorbidity was determined by the number of chronic
diseases that required maintenance treatment.
2.2. Statistical Analysis. Fisher’s exact test (for categorical
data) and Student’s t-test (for continuous variables) were
used for comparisons between two diﬀerent groups. Each
value is reported as percentage frequencies or means ±
standard error (SEM). Survival curves were generated using
the Kaplan-Meier method. Survival was deﬁned as the time
between the hospital admission and death. Survival was
censored up to patients’ last followup. Cox proportional
hazards regression modeling was used to examine long-
term survival in ADPKD and non-ADPKD adjusted for age
diﬀerence. Logistic regression analysis was also conducted
controlling for several known risk factors for AKI. A two-
tailed P value of <0.05 was considered signiﬁcant. All the
analyses were performed using JMP version 8 and GraphPad
statistical software.
3. Results
3.1. Patient Characteristics. Of the 63 patients admitted for
acute pneumonia, all of them had chest X-ray evidence of
lobar inﬁltrative and/or consolidative processes consistent
with pneumonia. Thirty-nine of the 63 were excluded
because of end-stage renal failure on dialysis (19 cases),
after kidney transplantation (14 cases), incomplete clinical
information (4 cases), and on immunosuppressive ther-
apy for other reasons, systemic vasculitis, and rheumatoid
arthritis (2 cases). The remaining 23 of the 24 ADPKD
patients were matched with 92 (1:4 ratio) non-ADPKD
patients with comparable baseline eGFR who were admitted
for pneumonia (with chest X-rays showing lobar inﬁltration
and/or consolidation) during the same time period. One of
the 24 ADPKD patients had eGFR of 7mL/min/1.73m2 and
was not on dialysis. We were unable to identify any non-
ADPKD patient with similar eGFR not on dialysis.
As shown in Table 1, the baseline characteristics of
ADPKD and non-ADPKD patients were similar except
for non-ADPKD patients being signiﬁcantly older and
showing a higher number of comorbidities. Comorbid
conditions seen more often in non-ADPKD patients were
atrialﬁbrillationonanticoagulation,congestiveheartfailure,
severe valvular heart diseases, and hypothyroidism. There
was no diﬀerence in the incidence of nephrotoxic medi-
cation exposure, including NSAIDs, intravenous contrast,
diuretic therapy, angiotensin converting enzyme inhibitor,
and angiotensin receptor blocker between ADPKD and non-
ADPKD patients. For ADPKD patients, there was a tendency
towards male predominance.
3.2.Incidence and Severity of AKI inPatientswithPneumonia.
Of the 23 ADPKD patients, 16 (69.6%) developed AKI.
Of the 92 non-ADPKD patients, 36 (39.1%) developed
AKI. The frequency of AKI was signiﬁcantly higher in
patients with ADPKD, P = 0.008. This diﬀerence occurred
despite the age advantage and lesser comorbidity in ADPKD
patients, suggesting a predilection among ADPKD patients
for developing AKI.
To characterize AKI severity, patients with AKI were
stratiﬁed based on the magnitude of their serum creatinine
elevation, according to the RIFLE criteria. As shown in
Table 2, the distribution of AKI severity was not statistically
diﬀerent in this cohort, although ﬁve of 16 (31.3%) ADPKD
patients were in the category of failure whereas two of 36
(5.56%) non-ADPKD patients were in the same category.
3.3. Characteristics and Hospital Course of Patients with
and without AKI. We further compared ADPKD and non-
ADPKD patients with and without AKI (Table 3). The base-
line eGFR was lower in patients with AKI in both ADPKD
and non-ADPKD groups, with statistical signiﬁcance inInternational Journal of Nephrology 3
Table 1: Baseline characteristics of patients with and without ADPKD.
ADPKD Non-ADPKD P
N, pneumonia episodes 23 92
Baseline eGFR mL/min/1.73m2 (mean, SEM) 46.4 ± 5.13 47.3 ± 2.05 0.88
Age (mean, range), years 59.7 (31–88) 81.9 (99–25) <0.0001
Male/female 17/6 49/43 0.07
Pneumonia severity score (mean, SEM1)1 . 9 5 ± 0.22 2.26 ± 0.08 0.21
Smoking (%) 12 (54.5%) 56 (60.87%) 0.73
Diabetes (%) 5 (21.7) 21 (22.8) 0.91
Hypertension (%) 20 (87.0) 74 (80.4) 0.46
Coronary artery disease (%) 10 (43.5) 50 (54.4) 0.35
N of disease diagnosis (mean, SEM) 5.26 ± 0.56 8.96 ± 0.33 <0.0001
1SEM: standard error of the mean.
Table 2: AKI in pneumonia patients with and without ADPKD.
ADPKD (n = 23) Non-ADPKD (n = 92) 1P
AKI episode, number (%) 16 (69.6) 36 (39.1) 0.008
AKI severity
Cr elevation ≥0.3 and <1.5-fold (%) 5 (31.3) 9 (25.0) 0.73
2Risk, number (%) 3 (18.8) 17 (47.2) 0.06
3Injury, number (%) 1 (6.25) 2 (5.56) 1
4Failure, number (%) 5 (31.3) 2 (5.56) 0.02
Dialysis, number (%) 2 (12.5) 6 (16.7) 1
1P value adjusted for age. 2Risk: serum creatinine (Cr) increase ≥1.5 fold. 3Injury: serum Cr increase ≥2f o l d .4Failure: serum Cr increase ≥3f o l do rs e r u m
Cr >4mg/dL.
Table 3: Patient characteristics and clinical course in ADPKD and non-ADPKD patients with and without AKI.
Patient characteristics ADPKD Non-ADPKD
− AKI (n = 7) + AKI (n = 16) P value − AKI (n = 56) + AKI (n = 36) P value
Age, year mean (range) 58.7 (34–82) 60.2 (31–88) 0.87 83.1 (62–99) 80.1 (25–99) 0.54
Gender (male), N (%) 3 (42.9) 14 (87.5) 0.02 29 (51.8) 20 (55.6) 0.72
Baseline eGFR Mean ± SEM (mL/min/1.73m2) 58.7 ± 11.8 41.1 ± 5.00 0.20 51.8 ± 2.24 40.2 ± 3.65 0.009
Comorbidity, number of diagnosis 5.28 ± 1.42 5.25 ± 0.55 0.98 8.89 ± 0.49 9.08 ± 0.57 0.80
Clinical course
Hospital stay (days) mean ± SEM 3.28 ± 0.91 16.3 ± 4.23 0.008 5.32 ± 0.73 20.1 ± 7.28 0.05
ICU admission, patient number (%) 0 8 (50) 0.02 8 (14.29) 16 (44.44) 0.001
Vasopressor use, patient number (%) 0 3 (18.75) 0.21 1 (1.79) 8 (22.22) 0.001
Mechanical ventilation (number) 0 5 (31.25) 0.09 1 (1.79) 7 (19.44) 0.003
the non-ADPKD group. This is consistent with preexisting
kidney dysfunction as a risk factor for AKI. The number
of medical comorbidities was not diﬀerent in patients with
or without AKI. We also compared the clinical course of
those with and without AKI. In both groups, patients with
AKI required a longer hospital stay than those without
AKI (Table 3, clinical course). Similarly, patients with AKI
required more ICU admissions, inotropic administration,
and mechanical ventilation compared to patients without
AKI.
To investigate the contribution of known risk factors of
AKI in this patient cohort, logistic regression analysis was
performed. As shown in Table 4,b a s e l i n ee G F R ,C U R B 6 5 ,
diabetes, and pressor administration were independent risk
factors for AKI. Notably, after adjusting for all confounding
variables, ADPKD remained an independent risk factor for
AKI.
3.4. Survival Analysis in ADPKD and Non-ADPKD Patients
with AKI. Hospital mortality was more common in patients
with AKI in both groups, two versus zero in ADPKD
and seven versus three in non-ADPKD group. We further
examined survival rates in AKI patients with and without4 International Journal of Nephrology
Table 4: Multivariate analysis for AKI risk factors in the entire cohort (N = 115).
Variable Odds ratio CI 95% P value
Baseline eGFR 0.95 0.92, 0.98 0.005
CURB65 score 1.86 1.02, 3.59 0.05
CAD 1.13 0.68, 1.87 0.63
HTN 0.62 0.33, 1.12 0.12
DM 1.94 1.10, 3.55 0.02
Hypotension requiring pressors 5.91 2.11, 29.5 0.005
ADPKD 2.42 1.33, 4.81 0.006
Table 5: Cox proportional hazards model showing the eﬀect of age, AKI, and ADPKD on mortality.
Variable Hazard ratio 95% CI P value
ADPKD 0.75 0.43, 1.18 0.17
AKI 1.40 1.08, 1.08 0.01
Age 1.05 1.02, 1.08 <0.0001
ADPKD. The 30-day mortality rate for the ADPKD group
was 12.5% in AKI and 0% in non-AKI patients, and for the
non-ADPKD group 19.5% in AKI and 10.9% in non-AKI
patients although the absolute patient number was small.
When using Kaplan Meier analysis, as shown in Figures 1(a)
and 1(b), there was higher number of deaths in patients with
AKI in the ADPKD group, but statistical signiﬁcance was
not reached likely due to the small patient number; in non-
ADPKD patients, there was a statistically signiﬁcant increase
in mortality in patients with AKI.
We also performed Cox proportional hazards model,
correcting for the age diﬀerence between the non-ADPKD
and ADPKD groups. AKI and older age were signiﬁcantly
associated with higher mortality. ADPKD status did not
inﬂuence the AKI-associated mortality in this analysis
(Table 5).
4. Discussion
Toourknowledge,thisstudyrepresentstheﬁrstinvestigation
ofAKIinpatientswithADPKDinthesettingofaninfectious
process. It shows that in the context of pneumonia, ADPKD
patients exhibit a signiﬁcantly higher occurrence of AKI than
non-ADPKD patients with a comparable baseline eGFR.
ADPKD is the most common monogenic kidney disease,
aﬀecting 1 in 400 to 1:1000 livebirths. Mutations in the
PKD1 or PKD2 gene, encoding polycystin-1 and polycystin-
2, respectively, are responsible for the disease manifestations
[4]. Considerable data indicate that polycystins may form
a macromolecular signaling structure, the polycystin com-
plex, that regulates fundamental aspects of renal epithelial
function, including cell cycle progression and cell survival
[15]. PKD mutations in animal models have been shown
to cause dysregulation in polycystin-mediated signaling,
leading to abnormal proliferation and apoptosis. Abnormal
elevations in cellular proliferation and apoptosis have been
demonstrated in both cystic and noncystic renal tubular cells
in human ADPKD [5, 6].
Severalrecentstudiesbyindependentgroupshaveshown
that othologous PKD mutant mice are more susceptible
to kidney ischemic reperfusion injury resulting in more
extensive renal tubular destruction [7–9]. Moreover, repair
mechanisms are defective with evidence of dysregulated
proliferation in tubular cells and higher levels of interstitial
inﬂammation and ﬁbrosis, leading to permanent loss of
kidney function [7–9]. These observations suggest that PKD
geneproducts,polycystins,exertkeyrolesinregulatingtubu-
lar maintenance, susceptibility to injury, and mechanisms
of repair. Although these animal studies have shed light
on the pathways of kidney injury and repair in relation to
PKDmutations,thesusceptibilityofhumanADPKDkidneys
to AKI and the severity of AKI have not been previously
examined. Our observed increase in AKI occurrence, albeit
in a diﬀerent setting (pneumonia), is consistent with studies
generated from animal models of ADPKD.
The occurrence of AKI in the context of pneumonia has
been reported recently by Murugan et al. [10]. In that study,
AKI occurrence rate ranged between 16 and 30% depending
on the pneumonia severity. In our cohort, the non-ADPKD
patients showed a higher occurrence of AKI (39.1%). This
increased rate could have potentially been related to the age
diﬀerence between the two studies, as patients in our non-
ADPKD cohort were older (mean age of 80.1 years in AKI
and 83.1 years in non-AKI) compared to mean ages of 73.4
inAKIand65.2innon-AKIpatientsinthestudybyMurugan
et al.
Older age is a known risk factor for AKI [1]. Age-related
changes in the kidney and renal vasculature are thought to
account for the increased risk [1, 16]. Moreover, decreased
renal perfusion has been shown to be among the most
important causes of AKI [1]. Further, the Consortium for
Radiologic Imaging Studies of Polycystic Kidney Disease
(CRISP) [17] has shown that ADPKD kidneys display
a signiﬁcant reduction in renal perfusion earlier in age
with preserved kidney function (eGFR >70mL/min/BSA).
Such ADPKD-related renal hemodynamic changes could
render ADPKD kidneys vulnerable for developing AKI. It isInternational Journal of Nephrology 5
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(b) Kaplan Meier curve for ADPKD patients
Figure 1: Survival analysis of non-ADPKD patients (a) and ADPKD patients (b) with no AKI versus AKI.
therefore possible that, in addition to inherent renal tubular
defects, reduction in renal perfusion in ADPKD kidneys
plays an important role in the genesis of AKI, oﬀsetting the
eﬀects of age. In our study, ADPKD itself appeared to be a
risk factor for AKI, but not for mortality.
Several limitations in this study are worth noting. First,
the retrospective nature of the study limited the consistency
of blood sampling which could inﬂuence the levels of
peak and discharge creatinine concentrations. However, this
would be expected to aﬀect both ADPKD and non-ADPKD
patients in the same fashion. Second, the GFR used in this
study was estimated from converting serum creatinine to
eGFR using the MDRD equation, which is not as precise
as measured GFR, that is, iothalamate clearance. However,
the eGFR generated by this method is generally accepted as
a surrogate marker for kidney function. Third, this study
enrolled patients over a 20-year time-span. The level of
intensity in the clinical observation and documentation
could vary; brief changes in respiratory rates and changes
in blood pressure might have gone unrecorded, leading
to a potential underestimation of the pneumonia score.
Fortunately, our study subjects were from a single medical
center, where care protocol has not changed qualitatively,
especiallyintheinitialadmissionevaluationforpatientswith
signs of infection (the time for establishing the pneumonia
score). Moreover, any diﬀerences in routine care would
have applied to both ADPKD and non-ADPKD groups and
standardized diagnostic criteria for pneumonia were applied
to all study subjects. Fourth, the sample size for ADPKD is
relatively small. This could be explained by the following (1)
only a small fraction of pneumonia cases was hospitalized,
(2) patients admitted were local residents; without referral,
the relatively low prevalence of ADPKD limited the number
of cases, and (3) more than 50% of ADPKD patients with
pneumonia and admitted to hospital were excluded due
to end-stage renal disease on dialysis and renal transplant.
Finally, this study was limited by older age and a higher
level of comorbidity in non-ADPKD patients (Table 1).
Such diﬀerences could have introduced bias to the AKI
occurrence and, possibly, severity. However, because aging
and medical comorbidity are risk factors for AKI, such bias
introduced here would be towards worse kidney outcome
in the non-ADPKD group. The fact that AKI occurrence
was higher despite the age advantage and less comorbidity
in the ADPKD group, made the study results even more
compelling.Takentogether,limitationsinherentinthisstudy
would not change the study results. Conclusion
5. Conclusion
Toourknowledge,thisstudyrepresentstheﬁrstinvestigation
ofAKIinpatientswithADPKDinthesettingofaninfectious
process. The results show that ADPKD patients are more
vulnerable to the development of AKI in the context of
pneumonia, suggesting that ADPKD itself is a risk factor for
AKI. Further studies are needed to conﬁrm our ﬁndings.
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